Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Darusentan

Darusentan

Darusentan structure

Darusentan 

structure
  • CAS No:

    171714-84-4

  • Formula:

    C22H22N2O6

  • Chemical Name:

    Darusentan

  • Synonyms:

    Benzenepropanoic acid,α-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-,(αS)-;Benzenepropanoic acid,α-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-,(S)-;(αS)-α-[(4,6-Dimethoxy-2-pyrimidinyl)oxy]-β-methoxy-β-phenylbenzenepropanoic acid;Lu 135252;Darusentan;(+)-(2S)-2-[(4,6-Dimethoxypyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid;(+)-2(S)-(4,6-Dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid;177036-80-5

Description

Darusentan is a selective endothelin A (ETA) receptor antagonist. Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki=13 nM[1].


Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

Darusentan Basic Attributes

410.424

410.42

605-614-8

33JD57L6RW

DTXSID1057664

Characteristics

100

3.6

1.268±0.06 g/cm3(Predicted)

587.3±60.0 °C(Predicted)

309.0±32.9 °C

1.583

Drug Information

For the treatment of congestive heart failure and hypertension.

Darusentan is a selective endothelin ETA receptor antagonist.

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)

The mode of action by which the endothelin receptor antagonists cause a decrease of the BP is not yet totally elucidated; however, peripheral vasodilatation due to blockade of the vasoconstrictor effects of endothelin is the most likely explanation. A reduction of cardiac contractility is considered unlikely. Several studies have been published that investigated the effects of either selective or nonselective endothelin receptor blockade in patients with heart failure. In these studies, application of endothelin antagonists, while decreasing both systemic and pulmonary BP increased cardiac index and did not alter cardiac contractility or heart rate.

(+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid

Computed Properties

Molecular Weight:410.4
XLogP3:3.6
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:9
Exact Mass:410.14778643
Monoisotopic Mass:410.14778643
Topological Polar Surface Area:100
Heavy Atom Count:30
Complexity:506
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.